Sodium Bicarbonate
NDC Package 0409-4916-34

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Sodium Bicarbonate is injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Marketed by Hospira, Inc., this product is identified by NDC 0409-4916.

Identification & Billing

NDC Package Code
0409-4916-34
Package Description
10 CARTON in 1 PACKAGE / 1 SYRINGE in 1 CARTON / 50 mL in 1 SYRINGE
Product Code
0409-4916
11-Digit Billing Format
00409491634
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 727995 - sodium bicarbonate 7.5 % (44.6 MEQ) in 50 ML Prefilled Syringe
  • RxCUI: 727995 - 50 ML sodium bicarbonate 75 MG/ML Prefilled Syringe
  • RxCUI: 727995 - 50 ML NaHCO3 75 MG/ML Prefilled Syringe
  • RxCUI: 792582 - sodium bicarbonate 8.4 % (50 MEQ) in 50 ML Prefilled Syringe
  • RxCUI: 792582 - 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe

Clinical Specifications

Proprietary Name
Sodium Bicarbonate
Dosage Form
-
Usage Information
Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate.Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself.Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis.

Regulatory & Marketing

Labeler Name
Hospira, Inc.
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
02-16-2006
End Marketing Date
01-31-2023
Listing Expiration
01-31-2023
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0409-4916). Click a package code to view its specific billing and regulatory data.

0409-4916-14
10 CARTON in 1 PACKAGE / 1 SYRINGE in 1 CARTON / 50 mL in 1 SYRINGE (0409-4916-24)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0409-4916-34 identifies a specific commercial package of 10 carton in 1 package / 1 syringe in 1 carton / 50 ml in 1 syringe of Sodium Bicarbonate, labeled by Hospira, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Hospira, Inc. on February 16, 2006. The current certification is valid through January 31, 2023.

How is this Hospira, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00409491634. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0409-4916-34
11-Digit CMS (5-4-2)
00409-4916-34

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.